Initiator Pharma A/S (STO:INIT)

Market Cap	204.67M -41.6%
Revenue (ttm)	n/a
Net Income	-33.16M
EPS	n/a
Shares Out	68.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,529
Average Volume	162,072
Open	3.020
Previous Close	2.990
Day's Range	2.960 - 3.090
52-Week Range	2.560 - 4.170
Beta	0.11
RSI	42.70
Earnings Date	May 8, 2026

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to treat neuropathic pain; and IP2018, a monoamine reuptake inhibitor which completed Phase IIa for the treatment of psychogenic erectile dysfunction. The ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: INIT

Financial Performance

Financial numbers in DKK